The use of thalidomide in androgen-independent prostate cancer.

[1]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[2]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[3]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[4]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Neal,et al.  An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer , 2003, British Journal of Cancer.

[6]  H. Parnes,et al.  Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer , 2003, Pharmacotherapy.

[7]  Y. Ando,et al.  Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide , 2002, Cancer biology & therapy.

[8]  J. Zeldis,et al.  Thalidomide in the treatment of leprosy. , 2002, Microbes and infection.

[9]  W. Figg,et al.  Thalidomide metabolism by the CYP2C subfamily. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  A. Bergh,et al.  Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. , 2001, Scandinavian journal of urology and nephrology.

[11]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  E. Small,et al.  An update on prostate cancer , 2001, Current opinion in oncology.

[13]  P. Kantoff,et al.  Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. , 2001, Cancer research.

[14]  Jones,et al.  Angiogenesis in urological malignancy: prognostic indicator and therapeutic target , 1999, BJU international.

[15]  D. Bostwick,et al.  Microvessel density in prostate cancer: prognostic and therapeutic utility. , 1998, Seminars in urologic oncology.

[16]  W. Figg,et al.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.

[17]  A. Harris,et al.  Angiogenesis in urological malignancy. , 1995, British journal of urology.

[18]  M. Brawer,et al.  Topography of neovascularity in human prostate carcinoma , 1995, Cancer.

[19]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[20]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[21]  H. Sasaki,et al.  Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study , 1992, The Journal of pathology.

[22]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[23]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[24]  W. Lenz.  A short history of thalidomide embryopathy. , 1988, Teratology.

[25]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.